Johnson & Johnson ($JNJ) - Big Pharma's Q3 2010 Earnings Report

FiercePharma says: J&J's third quarter was down 0.7 percent compared to the third quarter of 2009; however, sales were slightly up compared to the same timeframe, at $1.23 per share. Though U.S. sales declined 2.5 percent, the Asia-Pacific Africa region grew 4.1 percent, the strongest growth of the quarter. The company's consumer segment is still lagging--and mired with manufacturing issues--down 10.2 percent compared to 2009's third quarter; U.S. sales in this department were down 24.5 percent, and OTC product sales were down 19.4 percent--with a 40 percent loss in the U.S. and a slight gain (3.5 percent) overseas.


  • Sales of $15.0 Billion Decreased 0.7% Versus 2009 Third-Quarter
  • EPS of $1.23 increased 2.5% Versus 2009 Third-Quarter

See J&J's current stock quote from CNN Money

J&J's website:
J&J's full earnings release: J&J release

Johnson & Johnson ($JNJ) - Big Pharma's Q3 2010 Earnings Report

Suggested Articles

Only months removed from a gamechanging label expansion for Vascepa, Amarin is scrambling after a district judge invalidated the drug's key patents.

Move over, Roche. There’s a new small-cell lung cancer therapy on the scene, and it belongs to AstraZeneca.

Fujifilm says it is prepared to ramp up production of Avigan for any country that wants to try it as a potential treatment for COVID-19.